Jpmorgan Chase & CO Biocryst Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 474,376 shares of BCRX stock, worth $4.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

474,376

Previous 577,129 17.8%

Holding current value

$4.37 Million

Previous $4.39 Million 18.67%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$7.03 - $8.43 $722,353 - $866,207	-102,753 Reduced 17.8%	474,376 $3.57 Million
Q3 2024 Dec 26, 2024	SELL	$6.41 - $8.69 $1.09 Million - $1.48 Million	-170,402 Reduced 22.8%	577,129 $4.39 Million
Q3 2024 Nov 08, 2024	SELL	$6.41 - $8.69 $1.09 Million - $1.48 Million	-170,402 Reduced 22.8%	577,129 $4.39 Million
Q2 2024 Dec 26, 2024	BUY	$4.13 - $6.79 $703,760 - $1.16 Million	170,402 Added 29.53%	747,531 $4.62 Million
Q2 2024 Aug 12, 2024	BUY	$4.13 - $6.79 $1.98 Million - $3.25 Million	478,455 Added 177.81%	747,531 $4.62 Million
Q1 2024 Dec 26, 2024	SELL	$4.89 - $7.65 $1.51 Million - $2.36 Million	-308,053 Reduced 53.38%	269,076 $1.37 Million
Q1 2024 May 10, 2024	SELL	$4.89 - $7.65 $1.36 Million - $2.13 Million	-278,461 Reduced 50.86%	269,076 $1.37 Million
Q4 2023 Dec 26, 2024	SELL	$4.98 - $6.77 $147,368 - $200,337	-29,592 Reduced 5.13%	547,537 $3.28 Million
Q4 2023 Feb 12, 2024	SELL	$4.98 - $6.77 $303,670 - $412,821	-60,978 Reduced 10.02%	547,537 $3.28 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $7.92 $154,330 - $182,160	-23,000 Reduced 3.64%	608,515 $4.31 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $220,618 - $279,259	31,698 Added 5.28%	631,515 $4.45 Million
Q1 2023 May 18, 2023	BUY	$7.94 - $11.84 $1.85 Million - $2.76 Million	233,395 Added 63.7%	599,817 $5 Million
Q1 2023 May 11, 2023	SELL	$7.94 - $11.84 $3.4 Million - $5.07 Million	-428,115 Reduced 53.88%	366,422 $3.06 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $213,507 - $288,742	20,334 Added 2.63%	794,537 $9.12 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $2.43 Million - $3.33 Million	225,163 Added 41.01%	774,203 $9.76 Million
Q2 2022 Aug 11, 2022	BUY	$7.89 - $17.88 $2.75 Million - $6.24 Million	348,759 Added 174.13%	549,040 $5.81 Million
Q1 2022 May 11, 2022	BUY	$11.56 - $19.76 $206,033 - $352,182	17,823 Added 9.77%	200,281 $3.26 Million
Q4 2021 Feb 10, 2022	SELL	$11.18 - $15.46 $40,527 - $56,042	-3,625 Reduced 1.95%	182,458 $2.53 Million
Q3 2021 Nov 12, 2021	BUY	$14.21 - $17.65 $2.64 Million - $3.28 Million	186,083 New	186,083 $2.67 Million

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

167M

Call Options Held

728K

Put Options Held

989K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.71B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Biocryst Pharmaceuticals Inc Transaction History